North Carolina Headlines

(Albany, New York) – 2nd Sep 2026 – The market dynamics for Peripheral T-cell Lymphoma (PTCL) are witnessing steady growth driven by the rising incidence of PTCL, improved disease recognition and classification, advancements in molecular diagnostics, and the increasing need for effective therapies for relapsed/refractory patients. Additionally, the emergence of targeted therapies such as golidocitinib, duvelisib, lacutamab, linperlisib, and soquelitinib, along with continued development of biologically guided treatment approaches, is expected to further propel the Peripheral T-cell Lymphoma market during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Peripheral T-cell lymphoma (PTCL) Market Insights, Epidemiology and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Peripheral T-cell Lymphoma, including historical and forecasted epidemiology, market trends, treatment scenarios, patient burden, and competitive landscape across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Peripheral T-cell Lymphoma Market

• The market size for Peripheral T-cell Lymphoma in the leading markets is expected to grow significantly by 2036.

• The 7MM Peripheral T-cell Lymphoma market was approximately USD 800 million in 2025 and is projected to reach nearly USD 1,600 million by 2036, reflecting a ~7% CAGR during 2026–2036.

• According to DelveInsight’s estimates, the United States accounted for approximately 12,000 incident cases of PTCL in 2025, with the number expected to increase by 2036.

• PTCL is a rare and heterogeneous group of aggressive T-cell lymphomas, accounting for approximately 10–15% of non-Hodgkin lymphomas in the US, 6.5% in the EU, and 25% in Japan.

• In 2025, PTCL was most frequently diagnosed at advanced stages (III/IV), reflecting the aggressive biology of many PTCL subtypes and delays in early recognition.

• Among EU4 and the UK, Germany accounted for approximately 1,270 PTCL cases in 2025, followed by France and the UK.

• The United States is expected to account for approximately 68% of the overall PTCL market by 2036 across the 7MM.

• In the 7MM, ADCETRIS held the largest market share in 2025, generating more than USD 300 million.

• Japan serves as a primary hub for PTCL therapies, with the majority of treatment approvals concentrated in the country.

• Leading Peripheral T-cell Lymphoma companies, including Pfizer, Kyowa Kirin, Citius Pharmaceuticals, Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceutical, Corvus Pharmaceuticals, and others, are actively developing innovative therapies expected to transform the PTCL treatment landscape over the coming years.

• Promising Peripheral T-cell Lymphoma therapies in clinical development include Duvelisib (COPIKTRA), Golidocitinib, Linperlisib, Lacutamab, Soquelitinib, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Key Factors Driving the Peripheral T-cell Lymphoma MarketRising PTCL Incidence

The increasing incidence of PTCL across the 7MM is driven by improved disease recognition and classification, wider use of molecular diagnostics, an aging population, and increasing recognition of cases that may previously have been misclassified. In the United States, approximately 12,000 incident cases of PTCL were reported in 2025, with the patient pool expected to increase during the forecast period.

Rising Opportunities in Relapsed/Refractory Patient Pool

Relapsed/refractory PTCL remains a significant area of unmet need due to high relapse rates and the absence of an established standard of care. The introduction of therapies such as HIYASTA, DARVIAS, and REMITORO in Japan has expanded treatment options for patients with R/R PTCL and ATLL.

Expansion of Targeted and Biologically Guided Therapies

The PTCL pipeline is increasingly focused on targeted approaches designed to address specific biological drivers of disease. Emerging therapies such as golidocitinib, a JAK1 inhibitor; lacutamab, an anti-KIR3DL2 antibody; linperlisib, a selective PI3Kδ inhibitor; and duvelisib, a PI3Kδ/γ inhibitor, are expanding the potential treatment landscape.

Growing Focus on Novel Treatment Approaches

Despite advances in treatment, PTCL continues to be associated with poor outcomes, particularly in high-risk subtypes such as PTCL-NOS and AITL/TFH. The need for safer, more effective, biologically guided therapies with broad subtype applicability is expected to drive continued investment in clinical development and innovation.

Peripheral T-cell Lymphoma Competitive Landscape

The Peripheral T-cell Lymphoma treatment landscape remains centered on multi-agent chemotherapy, with CHOP historically serving as the standard first-line treatment. For CD30-positive PTCL, particularly systemic anaplastic large cell lymphoma (ALCL), treatment has increasingly shifted toward ADCETRIS (brentuximab vedotin) combined with CHP, based on improved outcomes compared with CHOP.

For relapsed/refractory disease, treatment options include HDAC inhibitors such as belinostat and romidepsin, pralatrexate, brentuximab vedotin for CD30-expressing disease, PI3K inhibitors, and other targeted and immune-modulating approaches. Stem cell transplantation may also be considered in selected patients.

The approved treatment landscape includes ADCETRIS, BELEODAQ, POTELIGEO, XALKORI, and EZHARMIA, although these therapies generally provide benefits in specific subtypes or treatment settings. Japan has emerged as an important market for approved PTCL therapies, with several treatments receiving approval for relapsed/refractory PTCL and ATLL.

The emerging pipeline is increasingly defined by targeted therapies. Duvelisib (COPIKTRA) is an oral PI3Kδ/γ inhibitor being evaluated in R/R PTCL, while Golidocitinib targets JAK1. Lacutamab is a first-in-class anti-KIR3DL2 antibody, while Linperlisib selectively inhibits PI3Kδ. Soquelitinib is another emerging targeted therapy being evaluated in a registrational Phase III study in R/R PTCL.

These emerging therapies are expected to intensify competition and potentially reshape the Peripheral T-cell Lymphoma treatment landscape over the forecast period.

Discover more about therapies set to grab major Peripheral T-cell Lymphoma market share @ Peripheral T-cell Lymphoma Treatment Landscape

Recent Developments in the Peripheral T-cell Lymphoma Market

• In June 2026, primary results from the Phase II CHEPA trial were presented at the EHA Congress. The study evaluated a combination of brentuximab vedotin, CHP chemotherapy, and etoposide for newly diagnosed CD30-positive peripheral T-cell lymphomas and achieved a 76% complete metabolic response rate with manageable toxicity.

• In April 2026, Secura Bio announced that the Journal of Clinical Oncology published final results from the Phase II PRIMO trial of duvelisib (COPIKTRA) in patients with relapsed or refractory PTCL.

• In March 2026, Corvus Pharmaceuticals announced continued enrollment in a registrational Phase III clinical trial of soquelitinib in patients with R/R PTCL. The FDA has granted soquelitinib Orphan Drug Designation for T-cell lymphoma and Fast Track designation for adult patients with R/R PTCL after at least two lines of systemic therapy.

• In December 2025, Secura Bio presented extended follow-up analyses from its Phase II PRIMO trial at the 2025 ASH Annual Meeting, highlighting continued clinical activity and a manageable safety profile for duvelisib.

• In December 2025, Dizal Pharmaceutical presented new data for golidocitinib at the 67th ASH Annual Meeting, including results from newly diagnosed PTCL, R/R PTCL, rare PTCL subtypes, and PTCL-associated HLH.

What is Peripheral T-cell Lymphoma?

Peripheral T-cell Lymphoma (PTCL) is a rare and heterogeneous group of aggressive lymphomas arising from mature T lymphocytes. PTCLs account for approximately 10–15% of all non-Hodgkin lymphomas in the United States and comprise multiple nodal and systemic entities, including PTCL-not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), and adult T-cell leukemia/lymphoma (ATLL).

Patients commonly present with rapidly enlarging painless lymphadenopathy, fever, night sweats, weight loss, pruritus, and, in advanced cases, cytopenias, bleeding, or hepatosplenomegaly. Diagnosis can be challenging because PTCL may overlap with reactive, infectious, autoimmune, and other lymphoid conditions and therefore requires expert hematopathological evaluation.

PTCL is driven by genomic instability affecting T-cell differentiation, T-cell receptor signaling, epigenetic regulation, and immune checkpoints, contributing to its aggressive and heterogeneous nature.

Treatment is guided by histologic subtype, disease stage, and patient fitness. Frontline treatment generally involves anthracycline-based chemotherapy such as CHOP, while BV-CHP may be used for CD30-positive subtypes, particularly ALCL. Relapsed/refractory disease remains challenging and may require targeted therapies, clinical trials, or stem cell transplantation.

Peripheral T-cell Lymphoma Epidemiology Segmentation

The Peripheral T-cell Lymphoma epidemiology section provides insights into the historical and current PTCL patient pool and forecasted trends across the seven major markets. The Peripheral T-cell Lymphoma market report provides epidemiological analysis for the study period 2022–2036, segmented into:

• Total Incident Cases of Peripheral T-cell Lymphoma

• Stage-specific Incident Cases of Peripheral T-cell Lymphoma

• Type-specific Incident Cases of Peripheral T-cell Lymphoma

• CD30 Expression-specific Incident Cases of Peripheral T-cell Lymphoma

• Line-wise Treated Cases of Peripheral T-cell Lymphoma

Scope of the Peripheral T-cell Lymphoma Market Report

• Therapeutic Assessment: Current marketed and emerging therapies for Peripheral T-cell Lymphoma

• Peripheral T-cell Lymphoma Market Dynamics: Key market forecast assumptions, pricing trends, therapy uptake, market outlook, and patient burden

• Key Companies: Acrotech Biopharma, Seattle Genetics, SECURA BIO, Astex Pharmaceuticals/Otsuka Pharmaceutical, Dizal Pharmaceuticals, Pfizer, Kyowa Kirin, Citius Pharmaceuticals, Shanghai YingLi Pharmaceutical, Corvus Pharmaceuticals, and others

• Key Therapies: FOLOTYN/DIFOLTA (pralatrexate), BELEODAQ (belinostat), ADCETRIS, Duvelisib, Tolinapant ± ASTX727, Golidocitinib, Linperlisib, Lacutamab, Soquelitinib, and others

• Competitive Intelligence Analysis: SWOT Analysis and Conjoint Analysis

• Unmet Needs, KOL’s Views, Analyst’s Views, Peripheral T-cell Lymphoma Market Access and Reimbursement

To know more about Peripheral T-cell Lymphoma companies working in the treatment market, visit @ Peripheral T-cell Lymphoma Clinical Trials and Therapeutic Assessment

Table of Contents

• Peripheral T-cell Lymphoma Market Report Introduction

• Executive Summary for Peripheral T-cell Lymphoma

• Key Events of Peripheral T-cell Lymphoma

• SWOT Analysis of Peripheral T-cell Lymphoma

• Peripheral T-cell Lymphoma Patient Share (%) Overview at a Glance

• Peripheral T-cell Lymphoma Market Overview at a Glance

• Peripheral T-cell Lymphoma Background and Overview

• Peripheral T-cell Lymphoma Epidemiology and Patient Population

• Country-Specific Patient Population of Peripheral T-cell Lymphoma

• Peripheral T-cell Lymphoma Current Treatment and Medical Practices

• Peripheral T-cell Lymphoma Unmet Needs

• Peripheral T-cell Lymphoma Emerging Therapies

• Peripheral T-cell Lymphoma Market Outlook

• Country-Wise Peripheral T-cell Lymphoma Market Analysis (2022–2036)

• Peripheral T-cell Lymphoma Market Access and Reimbursement of Therapies

• Peripheral T-cell Lymphoma Market Drivers

• Peripheral T-cell Lymphoma Market Barriers

• Peripheral T-cell Lymphoma Appendix

• Peripheral T-cell Lymphoma Report Methodology

• DelveInsight Capabilities

• Disclaimer

• About DelveInsight

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/